CONTROVERSIES IN BIOEQUIVALENCE STUDIES

被引：62

作者：

STEINIJANS, VW ^{[1
]}

HAUSCHKE, D ^{[1
]}

JONKMAN, JHG ^{[1
]}

机构：

[1] PHARM BIO-RES INT BV,INST CLIN PHARMACOL,ZUIDLAREN,NETHERLANDS

来源：

关键词：

D O I：

10.2165/00003088-199222040-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：247 / 253

页数：7

共 41 条

[1] AHR G, 1991, CONTROLLED MODIFIED, P85
[2] A NEW PROCEDURE FOR TESTING EQUIVALENCE IN COMPARATIVE BIOAVAILABILITY AND OTHER CLINICAL-TRIALS
ANDERSON, S
HAUCK, WW
[J]. COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1983, 12 (23) : 2663 - 2692
[3] CONSIDERATION OF INDIVIDUAL BIOEQUIVALENCE
ANDERSON, S
HAUCK, WW
[J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (03): : 259 - 273
[4] BENEDIKT G, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1203
[5] BLUME H, 1989, PHARM IND, V51, P1025
[6] Blume H, 1988, PHARM ZTG, V133, P389
[7] BOXENBAUM H, 1984, PHARM RES-DORDR, V2, P82
[8] DILETTI E, 1991, INT J CLIN PHARM TH, V29, P1
[9] THE SUBJECT-BY-FORMULATION INTERACTION AS A CRITERION OF INTERCHANGEABILITY OF DRUGS
EKBOHM, G
MELANDER, H
[J]. BIOMETRICS, 1989, 45 (04) : 1249 - 1254
[10] ENDRENYI L, 1991, INT J CLIN PHARM TH, V29, P394